|
1
|
Ginsberg RJ, Kris K and Armstrong G:
Cancer of the lungCancer: Principles and practice of oncology. De
Vita VT Jr, Hellman S and Rosenberg SA: 4th. Lippincott,
Philadelphia: pp. 673–682. 1993
|
|
2
|
Travis WD, Travis LB and Devesa SS: Lung
cancer. Cancer. 75 (Suppl S1):191–202. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Paez JG, Jänne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sasaki H, Shimizu S, Endo K, et al: EGFR
and erbB2 mutation status in Japanese lung cancer patients. Int J
Cancer. 118:180–184. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fukuoka M, Wu YL, Thongprasert S, et al:
Biomarker analyses and final overall survival results from a phase
III, randomized, open-label, first-line study of gefitinib versus
carboplatin/paclitaxel in clinically selected patients with
advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol.
29:2866–2874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Soda M, Choi YL, Enomoto M, et al:
Identification of the transforming EML4-ALK fusion gene in
non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peyssonnaux C and Eychène A: The
Raf/MEK/ERK pathway: new concepts of activation. Biol Cell.
93:53–62. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Davies H, Bignell GR, Cox C, et al:
Mutations of the BRAF gene in human cancer. Nature. 417:949–954.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Flaherty KT, Puzanov I, Kim KB, et al:
Inhibition of mutated, activated BRAF in metastatic melanoma. N
Engl J Med. 363:809–819. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chapman PB, Hauschild A, Robert C, et al:
BRIM-3 Study Group: Improved survival with vemurafenib in melanoma
with BRAF V600E mutation. N Engl J Med. 364:2507–2516. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yancovitz M, Litterman A, Yoon J, et al:
Intra- and inter-tumor heterogeneity of BRAFV600E mutations in
primary and metastatic melanoma. PLoS One. 7:e293362012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marchetti A, Felicioni L, Malatesta S, et
al: Clinical features and outcome of patients with non-small-cell
lung cancer harboring BRAF mutations. J Clin Oncol. 29:3574–3579.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Paik PK, Arcila ME, Fara M, et al:
Clinical characteristics of patients with lung adenocarcinomas
harboring BRAF mutations. J Clin Oncol. 29:2046–2051. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peters S, Michielin O and Zimmermann S:
Dramatic response induced by vemurafenib in a BRAF V600E-mutated
lung adenocarcinoma. J Clin Oncol. 31:e341–e344. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gautschi O, Pauli C, Strobel K, et al: A
patient with BRAF V600E lung adenocarcinoma responding to
vemurafenib. J Thorac Oncol. 7:e23–e24. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sasaki H, Shitara M, Yokota K, et al: Braf
and erbB2 mutations correlate with smoking status in lung cancer
patients. Exp Ther Med. 3:771–775. 2012.PubMed/NCBI
|
|
17
|
Sasaki H, Shimizu S, Tani Y, et al:
Usefulness of immunohistochemistry for the detection of the BRAF
V600E mutation in Japanese lung adenocarcinoma. Lung Cancer.
82:51–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Didelot A, Le Corre D, Luscan A, et al:
Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR
mutation detection in clinical formalin fixed paraffin embedded
samples. Exp Mol Pathol. 92:275–280. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Endo K, Sasaki H, Yano M, et al:
Evaluation of the epidermal growth factor receptor gene mutation
and copy number in non-small cell lung cancer with gefitinib
therapy. Oncol Rep. 16:533–541. 2006.PubMed/NCBI
|
|
20
|
Sasaki H, Okuda K, Kawano O, et al: Nras
and Kras mutation in Japanese lung cancer patients: Genotyping
analysis using LightCycler. Oncol Rep. 18:623–628. 2007.PubMed/NCBI
|
|
21
|
Yokota K, Sasaki H, Okuda K, et al:
KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the
lung. Oncol Rep. 28:1187–1192. 2012.PubMed/NCBI
|
|
22
|
Shimuzu S, Yatabe Y, Koshikawa T, et al:
High frequency of clonally related tumors in cases of multiple
synchronous lung cancers as revealed by molecular diagnosis. Clin
Cancer Res. 6:3994–3999. 2000.PubMed/NCBI
|
|
23
|
Fidler IJ and Kripke ML: Metastasis
results from preexisting variant cells within a malignant tumor.
Science. 197:893–895. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Navin N, Kendall J, Troge J, et al: Tumour
evolution inferred by single-cell sequencing. Nature. 472:90–94.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Katona TM, Jones TD, Wang M, et al:
Genetically heterogeneous and clonally unrelated metastases may
arise in patients with cutaneous melanoma. Am J Surg Pathol.
31:1029–1037. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ligel B, Kepten I, Le C, et al:
Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J
Pathol. 216:64–74. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Taniguchi K, Okami J, Kodama K, et al:
Intratumor heterogeneity of epidermal growth factor receptor
mutations in lung cancer and its correlation to the response to
gefitinib. Cancer Sci. 99:929–935. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cardarella S, Oritz TM, Joshi VA, et al:
The introduction of systematic genomic testing for patients with
non-small-cell lung cancer. J Thorac Oncol. 7:1767–1774. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fecher LA, Amaravadi RK and Flaherty KT:
The MAPK pathway in melanoma. Curr Opin Oncol. 20:183–189. 2008.
View Article : Google Scholar : PubMed/NCBI
|
